Oncology/Hematology Market Research Reports & Industry Analysis
Oncology/Hematology Industry Research & Market Reports
-
Endometrial Cancer Treatment
... at a CAGR of 5.0% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$31.3 Billion by the end of the ... Read More
-
NDDS in Cancer Therapy
... 2030, growing at a CAGR of 20.7% over the analysis period 2024-2030. Nanoparticles, one of the segments analyzed in the report, is expected to record a 20.6% CAGR and reach US$67.8 Billion by the end ... Read More
-
Non-Small Cell Lung Cancer (NSCLC) Therapeutics
... reach US$54.0 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach ... Read More
-
Sarcoma Drugs
... CAGR of 7.6% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$1.9 Billion by the end of the analysis ... Read More
-
Veterinary Oncology
... CAGR of 10.9% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 12.0% CAGR and reach US$246.0 Million by the end of the analysis period. ... Read More
-
Lymphoma Therapeutics
... CAGR of 6.5% over the analysis period 2024-2030. Non-Hodgkin Lymphoma (NHL) Therapeutics, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$20.5 Billion by the end of ... Read More
-
Kidney Cancer Drugs
... at a CAGR of 4.8% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$5.6 Billion by the end of ... Read More
-
Melanoma Therapeutics
... CAGR of 13.7% over the analysis period 2024-2030. Cutaneous Melanoma Therapeutics, one of the segments analyzed in the report, is expected to record a 13.7% CAGR and reach US$4.3 Billion by the end of the ... Read More
-
Brachytherapy
... 4.3% over the analysis period 2024-2030. High Dose Rate Brachytherapy, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$1.6 Billion by the end of the analysis ... Read More
-
Oncology Nutrition
... CAGR of 9.6% over the analysis period 2024-2030. Head & Neck Cancer Nutrition, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$609.6 Million by the end ... Read More
-
Non-Hodgkin Lymphoma Therapeutics
... at a CAGR of 7.0% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$10.1 Billion by the end of the ... Read More
-
Cancer Diagnostics
... CAGR of 5.8% over the analysis period 2024-2030. Imaging, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$95.3 Billion by the end of the analysis period. ... Read More
-
Hematological Malignancies
... CAGR of 6.2% over the analysis period 2024-2030. Leukemia Disease, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$33.3 Billion by the end of the analysis ... Read More
-
Lung Cancer Therapeutics
... at a CAGR of 10.8% over the analysis period 2024-2030. Non-Small-Cell Lung Cancer (NSCLC) Therapeutics, one of the segments analyzed in the report, is expected to record a 11.9% CAGR and reach US$82.3 Billion by ... Read More
-
Uterine Cancer Therapeutics and Diagnostics
... Billion by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Endometrial Carcinomas Therapeutics & Diagnostics, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and ... Read More
-
Prescription Drugs
... CAGR of 5.7% over the analysis period 2024-2030. Generic Drugsone of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$498.0 Billion by the end of the analysis period. ... Read More
-
Cancer Therapies
... CAGR of 10.4% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$112.8 Billion by the end of the analysis period. ... Read More
-
Cancer Cachexia
... CAGR of 5.7% over the analysis period 2024-2030. Progestogens Therapy, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$1.5 Billion by the end of the analysis ... Read More
-
In-Vitro Colorectal Cancer Screening Tests
... Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Fecal Occult Blood Test, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach ... Read More
-
Cancer Vaccines
... CAGR of 9.3% over the analysis period 2024-2030. Preventive Vaccine, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$7.6 Billion by the end of the analysis ... Read More
-
Cancer Biomarkers
... CAGR of 16.9% over the analysis period 2024-2030. Protein Biomarkers, one of the segments analyzed in the report, is expected to record a 17.4% CAGR and reach US$42.9 Billion by the end of the analysis ... Read More
-
Cancer Immunotherapy Drug Discovery Outsourcing
... Billion by 2030, growing at a CAGR of 14.0% over the analysis period 2024-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 13.4% CAGR and reach US$1.5 Billion ... Read More
-
Prostate Cancer Diagnostics
... at a CAGR of 13.3% over the analysis period 2024-2030. Preliminary Test, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$10.0 Billion by the end of ... Read More
-
Breast Biopsy Devices
... at a CAGR of 5.6% over the analysis period 2024-2030. Biopsy Guidance Systems, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$983.4 Million by the end ... Read More
-
Bladder Cancer Therapeutics
... at a CAGR of 4.4% over the analysis period 2024-2030. Transitional Cell Bladder Cancer Therapeutics, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$114.6 Million by ... Read More
Research Assistance
